US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
June 12, 2024 12:18 ET
|
Spherix Global Insights
EXTON, PA, June 12, 2024 (GLOBE NEWSWIRE) -- Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative...
Insulin Delivery Devices Market Is Expected To Reach a Revenue Of USD 75.4 Bn By 2033, At 8.8% CAGR | Dimension Market Research
June 11, 2024 11:46 ET
|
Dimension Market Research
New York, June 11, 2024 (GLOBE NEWSWIRE) -- The Global Insulin Delivery Devices Market size is expected to reach USD 35.2 billion by 2024 and is further anticipated to reach USD 75.4 billion by 2033...
Biopharma Plastics Market Set for Strong Growth Trajectory, Targeting USD 18,130.3 Million by 2033 | Dimension Market Research
June 11, 2024 11:08 ET
|
Dimension Market Research
New York, June 11, 2024 (GLOBE NEWSWIRE) -- Overview: The Global Biopharma Plastics Market reached USD 5,695.3 million in 2023 and is further anticipated to reach USD 18,130.3 million by 2033...
Biopharmaceutical Market to Reach USD 1,829.2 Billion by 2033, Growing at 15.4% CAGR | Dimension Market Research
June 10, 2024 10:12 ET
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Overview: The Global Biopharmaceutical Market size reached USD 436.7 billion in 2023 and is further anticipated to reach USD 1,829.2 billion by 2033...
Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
June 10, 2024 04:00 ET
|
Spherix Global Insights
EXTON, PA, June 10, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
June 05, 2024 09:00 ET
|
Osteal Therapeutics
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
June 05, 2024 08:00 ET
|
PRISM MarketView
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
May 31, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth
May 30, 2024 07:00 ET
|
BTG Specialty Pharmaceuticals
Philadelphia, PA, May 30, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, has appointed Vanessa Wolfeler as its new Chief Executive Officer (CEO) effective...
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 29, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting